TPST Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Tempest Therapeutics Inc (TPST) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock lacks strong positive catalysts, has weak financial performance, and no significant trading signals or momentum indicators to suggest a compelling entry point at this time.
The MACD is positive and expanding, indicating bullish momentum, but the RSI is neutral at 73.218. Moving averages are converging, showing no clear trend. Key resistance levels are at 2.309 and 2.533, while support levels are at 1.583 and 1.359. The stock is currently trading pre-market at 2.21, down 1.34%, which is close to its resistance level.
The recent analyst upgrade by H.C. Wainwright highlights the acquisition of Factor Bioscience's CAR-T programs as a strategic move to extend the company's cash runway and expand its pipeline with a clinically de-risked asset.
Additionally, there is no recent news, no significant insider or hedge fund activity, and no congress trading data to indicate confidence in the stock.
In Q4 2025, revenue remained at 0 with no growth, net income dropped significantly to -$4,021,000 (-70.89% YoY), and EPS fell to -0.82 (-81.28% YoY). Gross margin remained at 0 with no improvement.
On January 22, 2026, H.C. Wainwright upgraded TPST to Buy with an $11 price target, citing strategic acquisitions and pipeline expansion. However, this upgrade alone does not outweigh the weak financials and lack of trading momentum.
